| Acromegaly
Somatuline Depot vs Somavert
Side-by-side clinical, coverage, and cost comparison for acromegaly.Deep comparison between: Somatuline Depot vs Somavert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSomavert has a higher rate of injection site reactions vs Somatuline Depot based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Somavert but not Somatuline Depot, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Somatuline Depot
Somavert
At A Glance
SC injection
Every 4 weeks
Somatostatin analog
SC injection
Daily
GH receptor antagonist
Indications
- Acromegaly
- Gastro-enteropancreatic neuroendocrine tumor
- Malignant Carcinoid Syndrome
- Acromegaly
Dosing
Acromegaly 90 mg deep SC injection every 4 weeks for 3 months; adjust thereafter to 60-120 mg every 4 weeks based on GH and/or IGF-1 levels; controlled patients may extend to 120 mg every 6 or 8 weeks. Starting dose reduced to 60 mg every 4 weeks in moderate or severe renal or hepatic impairment.
Gastro-enteropancreatic neuroendocrine tumor, Malignant Carcinoid Syndrome 120 mg deep SC injection every 4 weeks; if already receiving treatment for GEP-NET, do not administer an additional dose for carcinoid syndrome.
Acromegaly 40 mg SC loading dose under physician supervision, then 10 mg SC once daily starting the next day; titrate in 5 mg increments or decrements every 4-6 weeks to normalize IGF-1; maintenance range 10-30 mg SC once daily.
Contraindications
- History of hypersensitivity to lanreotide (including angioedema and anaphylaxis)
—
Adverse Reactions
Most common (>5%) Diarrhea, abdominal pain, nausea, constipation, flatulence, vomiting, loose stools, cholelithiasis, injection site reactions, musculoskeletal pain, arthralgia, headache, hyperglycemia, hypertension, dizziness
Serious Cholelithiasis and complications of cholelithiasis, hyperglycemia and hypoglycemia, cardiovascular abnormalities, thyroid function abnormalities, steatorrhea and malabsorption of dietary fats
Postmarketing Pancreatic exocrine insufficiency, steatorrhea, cholecystitis, cholangitis, pancreatitis, angioedema, anaphylaxis, injection site abscess
Most common Infection, pain, nausea, diarrhea, abnormal liver function tests, flu syndrome, injection site reaction, dizziness
Serious Transaminase elevations >10x ULN, hepatotoxicity, lipohypertrophy, systemic hypersensitivity reactions
Postmarketing Anaphylactic reactions, laryngospasm, angioedema, rash, erythema, pruritus, urticaria
Pharmacology
Lanreotide is a synthetic octapeptide analog of natural somatostatin with high binding affinity for somatostatin receptors SSTR2 and SSTR5; it inhibits growth hormone and IGF-1 secretion, reduces carcinoid syndrome mediators (urinary 5-HIAA), and suppresses various endocrine, neuroendocrine, exocrine, and paracrine functions.
GH receptor antagonist; pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, blocking endogenous GH binding and interfering with GH signal transduction, resulting in decreased serum concentrations of IGF-1, free IGF-1, ALS, and IGFBP-3.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Somatuline Depot
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Somavert
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Somatuline Depot
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Somavert
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (4/8)
Humana
Somatuline Depot
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Somavert
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Somavert Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Somatuline DepotView full Somatuline Depot profile
SomavertView full Somavert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.